Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EDIT Stock Forecast 2026-2027
$2.88
Current Price
$466.52M
Market Cap
Buy 7
Hold 4
Sell 2
Wall St Analyst Ratings
Distance to EDIT Price Targets
+420.8%
To High Target of $15.00
+73.6%
To Median Target of $5.00
-65.3%
To Low Target of $1.00
EDIT Price Momentum
-11.7%
1 Week Change
+7.1%
1 Month Change
+4.3%
1 Year Change
+40.5%
Year-to-Date Change
-36.5%
From 52W High of $4.54
+73.5%
From 52W Low of $1.66
📊 TOP ANALYST CALLS
Did EDIT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Editas Medicine is one of their latest high-conviction picks.
Latest EDIT Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, EDIT has a bullish consensus with a median price target of $5.00 (ranging from $1.00 to $15.00). The overall analyst rating is Buy (7.8/10). Currently trading at $2.88, the median forecast implies a 73.6% upside. This outlook is supported by 7 Buy, 4 Hold, and 2 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EDIT Analyst Ratings
7
Buy
4
Hold
2
Sell
EDIT Price Target Range
Low
$1.00
Average
$5.00
High
$15.00
Current: $2.88
Latest EDIT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EDIT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 5, 2026 | Chardan Capital | Geulah Livshits | Buy | Maintains | $4.00 |
| Mar 10, 2026 | Jones Trading | Buy | Upgrade | $N/A | |
| Mar 9, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Sep 5, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 3, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 13, 2025 | Baird | Outperform | Maintains | $N/A | |
| May 13, 2025 | Baird | Outperform | Maintains | $N/A | |
| Apr 28, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Dec 16, 2024 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Dec 16, 2024 | JP Morgan | Underweight | Downgrade | $N/A | |
| Dec 13, 2024 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Dec 13, 2024 | Barclays | Equal-Weight | Maintains | $N/A | |
| Dec 13, 2024 | Chardan Capital | Neutral | Downgrade | $N/A | |
| Dec 13, 2024 | Baird | Outperform | Maintains | $N/A | |
| Dec 13, 2024 | Stifel | Hold | Downgrade | $N/A | |
| Dec 11, 2024 | Wells Fargo | Equal-Weight | Downgrade | $N/A | |
| Nov 5, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 5, 2024 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Nov 5, 2024 | Stifel | Buy | Maintains | $N/A |
Editas Medicine Inc. (EDIT) Competitors
The following stocks are similar to Editas Medicine based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
EDIT
Editas Medicine
mkt cap
500.29M
Editas Medicine Inc. (EDIT) Financial Data
Editas Medicine Inc. has a market capitalization of $466.52M with a P/E ratio of -1.7x. The company generates $38.69M in trailing twelve-month revenue with a -281.6% profit margin.
Revenue growth is -39.2% quarter-over-quarter, while maintaining an operating margin of -883.2% and return on equity of -326.1%.
Valuation Metrics
Market Cap
$466.52M
Enterprise Value
$191.28M
P/E Ratio
-1.7x
PEG Ratio
0.0x
Price/Sales
12.1x
Growth & Margins
Revenue Growth (YoY)
-39.2%
Gross Margin
N/A
Operating Margin
-883.2%
Net Margin
-281.6%
EPS Growth
-39.2%
Financial Health
Cash/Price Ratio
+43.9%
Current Ratio
3.2x
Debt/Equity
392.4x
ROE
-326.1%
ROA
-26.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Editas Medicine Inc. (EDIT) Business Model
About Editas Medicine Inc.
What They Do
Develops CRISPR-based gene editing therapies.
Business Model
The company operates as a clinical-stage biotechnology firm, focusing on the discovery and development of CRISPR-based therapies for serious diseases. It generates revenue through the advancement of its gene editing programs, which target various conditions, and may eventually commercialize its treatments once they receive regulatory approval.
Additional Information
Editas Medicine Inc. is located in Cambridge, Massachusetts, with additional facilities in Boulder, Colorado. Its pipeline includes promising therapies like EDIT-101 for treating inherited blindness and utilizes advanced CRISPR nucleases to create effective treatments for genetic disorders, highlighting its commitment to addressing unmet healthcare needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
246
CEO
Dr. Gilmore O'Neill M.D.
Country
United States
IPO Year
2016
Website
www.editasmedicine.comEditas Medicine Inc. (EDIT) Latest News & Analysis
Latest News
The Healthcare M&A Wave
1 month ago
Quick Summary
This week's InnovationRx highlights biotech mergers and acquisitions, the emergence of India's Anthem Biosciences, and other industry trends.
Why It Matters
Biotech M&A activity and the emergence of companies like Anthem Biosciences signal market trends and potential investment opportunities in the growing biotech sector.
Source: Forbes
Market Sentiment:
Neutral
Quick Summary
Editas (EDIT) recently reported earnings 30 days ago. Investors should monitor upcoming developments and market reactions for insights on the stock's future performance.
Why It Matters
Editas' recent earnings report could signal future stock performance and investor sentiment, influencing buying or selling decisions based on growth potential or financial health.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Editas Medicine (Nasdaq: EDIT) will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:00 p.m. ET, focusing on gene editing for serious diseases.
Why It Matters
Editas Medicine's presentation at a major healthcare conference could signal upcoming developments or partnerships, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Editas Medicine's EDIT-401 showed ~90% reductions in LDL-C, Lp(a), and ApoB in non-human primates. The company plans to submit a CTN by mid-2026 and expects human data by late 2026.
Why It Matters
Positive preclinical results for EDIT-401 indicate strong potential in lowering key cardiovascular risk factors, enhancing Editas Medicine's prospects for future approvals and market success.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Editas Medicine, Inc. has initiated an underwritten public offering of common stock and accompanying warrants, with all securities being sold by the company.
Why It Matters
Editas Medicine's public offering may dilute existing shares and signal a need for capital, impacting stock price and investor sentiment regarding future growth and financial health.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Editas Medicine, Inc. priced a public offering of 55.6 million shares and warrants at $2.25 each, aiming for $125 million in gross proceeds. Potential proceeds could rise to $194.4 million if warrants are exercised.
Why It Matters
Editas Medicine's $125 million stock offering signals capital for growth, potentially enhancing its pipeline and market position. The exercise of warrants could further boost funding and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About EDIT Stock
What is Editas Medicine Inc.'s (EDIT) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Editas Medicine Inc. (EDIT) has a median price target of $5.00. The highest price target is $15.00 and the lowest is $1.00.
Is EDIT stock a good investment in 2027?
According to current analyst ratings, EDIT has 7 Buy ratings, 4 Hold ratings, and 2 Sell ratings. The stock is currently trading at $2.88. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EDIT stock?
Wall Street analysts predict EDIT stock could reach $5.00 in the next 12 months. This represents a 73.6% increase from the current price of $2.88. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Editas Medicine Inc.'s business model?
The company operates as a clinical-stage biotechnology firm, focusing on the discovery and development of CRISPR-based therapies for serious diseases. It generates revenue through the advancement of its gene editing programs, which target various conditions, and may eventually commercialize its treatments once they receive regulatory approval.
What is the highest forecasted price for EDIT Editas Medicine Inc.?
The highest price target for EDIT is $15.00 from at , which represents a 420.8% increase from the current price of $2.88.
What is the lowest forecasted price for EDIT Editas Medicine Inc.?
The lowest price target for EDIT is $1.00 from at , which represents a -65.3% decrease from the current price of $2.88.
What is the overall EDIT consensus from analysts for Editas Medicine Inc.?
The overall analyst consensus for EDIT is bullish. Out of 3 Wall Street analysts, 7 rate it as Buy, 4 as Hold, and 2 as Sell, with a median price target of $5.00.
How accurate are EDIT stock price projections?
Stock price projections, including those for Editas Medicine Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:27 AM UTC